Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Control Bionics Ltd. ( (AU:CBL) ) just unveiled an announcement.
Control Bionics Limited has successfully raised $0.6 million through a shortfall placement, supported by both new and existing shareholders. The funds will be used to enhance the company’s commercialization efforts in neurotechnology, particularly in the sports and rehabilitation markets, strengthening its position in these emerging sectors.
More about Control Bionics Ltd.
Control Bionics is a medical device company specializing in assistive technology for patients with communication impairments due to conditions like Motor Neurone Disease and Amyotrophic Lateral Sclerosis. Their core product, NeuroNode, is a wireless wearable device that captures brain signals to enable communication through computer interfaces. The company is expanding its technology into new markets such as health diagnostics, sports performance, and rehabilitation with its NeuroStrip device. Control Bionics operates in North America, Australia, Singapore, and Japan.
Average Trading Volume: 181,535
Technical Sentiment Signal: Sell
Current Market Cap: A$13.79M
Learn more about CBL stock on TipRanks’ Stock Analysis page.